RA Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

RA Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174M	Buy	17,955,642 +8,102,340	+82%	+$73.8M	1.51%	16
2026 Q1	$63.5M	Hold	9,853,302	–	–	0.67%	30
2025 Q4	$42.3M	Hold	9,853,302	–	–	0.43%	41
2025 Q3	$28.3M	Hold	9,853,302	–	–	0.35%	36
2025 Q2	$14.9M	Hold	9,853,302	–	–	0.25%	42
2025 Q1	$29.6M	Hold	9,853,302	–	–	0.49%	31
2024 Q4	$99.3M	Hold	9,853,302	–	–	1.32%	21
2024 Q3	$152M	Buy	+9,853,302	New	+$114M	1.76%	17

Other funds holding ARTV

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

RA Capital Management's ARTV Position: Q2 2026 in Review

RA Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 82% in Q2 2026, buying an estimated $73.8M and bringing the position to 17,955,642 shares worth $174M. The position accounts for 1.51% of the portfolio, ranked #16.

RA Capital Management first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

RA Capital Management held 17,955,642 shares of Artiva Biotherapeutics worth $174M as of Q2 2026.
RA Capital Management bought 8,102,340 Artiva Biotherapeutics shares in Q2 2026, an estimated $73.8M.
Artiva Biotherapeutics made up 1.51% of RA Capital Management's portfolio in Q2 2026, its #16 holding.
RA Capital Management first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.